You are paying for continuity: recurring clinician access, ongoing prescription management, and scheduled refills, in addition to the medication
The authors cautioned, however, that the issue requires additional research, and that those with a family history of medullary thyroid cancer should avoid GLP-1 RAs
Key results: 12 mg dose: Average weight loss of 24.2 percent of body weight 8 mg dose: Average weight loss of 22.8 percent 4 mg dose: Average weight loss of 17.0 percent Over 90 percent of participants at 8 or 12 mg lost at least 10 percent of body weight Over 75 percent at 12 mg lost at least 20 percent Crucially, the weight loss curve had not yet plateaued at 48 weeks, suggesting longer treatment may produce even greater results
Follow Slow Dose Escalation (4-Week Minimum) Stay at each dose for a full 4 weeks before increasing
Where is compounded tirzepatide produced
Unless specific circumstances favor Saxenda, semaglutide is the more effective and practical choice
